Comparison of antithrombotic effects between salvianolic acid A and aspirin
10.16438/j.0513-4870.2018-0895
- VernacularTitle:丹酚酸A与阿司匹林抗血栓作用的比较研究
- Author:
Hai-gang WANG
1
;
Ling-lei KONG
1
;
Rui WANG
1
,
2
;
Yan-xia CHEN
1
,
3
;
Shi-lun YANG
1
,
4
;
Xiao-yue ZHAO
1
;
Qi-meng ZHOU
1
;
Guan-hua DU
1
Author Information
1. Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Guangdong Pharmaceutical University, Guangzhou 510006, China
3. Baotou Medical College, Baotou 014040, China
4. Shenyang Pharmaceutical University, Shengyang 110016, China
- Publication Type:Research Article
- Keywords:
salvianolic acid A;
aspirin;
antiplatelet;
antithrombotic
- From:
Acta Pharmaceutica Sinica
2019;54(2):301-307
- CountryChina
- Language:Chinese
-
Abstract:
This study was designed to compare the antithrombotic effects of salvianolic acid A and aspirin. The anti-platelet aggregation and anticoagulant effects of salvianolic acid A and aspirin in vitro and in vivo were investigated in normal rats. The anti-cerebral ischemia and anti-platelet aggregation effects of salvianolic acid A and aspirin were also investigated in rats with thrombotic cerebral ischemia. All animal care and experimental procedures were reviewed and approved by the Animal Ethics Committee of Chinese Academy of Medical Sciences. The results of antiplatelet aggregation in vitro and in vivo showed that salvianolic acid A could mildly inhibit adenosine diphosphate (ADP), arachidonic acid (AA) and thrombin (THR)-induced antiplatelet aggregation in a dose-dependent manner, while aspirin played a strong inhibitory effect on AA-induced platelet aggregation in vivo. The effects of salvianolic acid A and aspirin on the coagulation system were similar. At the same time, the results of maximum platelet aggregation rate (MAR) in the rat cerebral ischemia model [MARADP= (41.67±4.55)%, MARAA= (53.22±2.83)%, MARTHR= (73.33±5.04)%] indicated that salvianolic acid A could mildly inhibit ADP and AA-induced antiplatelet aggregation [MARADP= (26.13±4.60)%, MARAA= (35.53±13.73)%, P<0.01], while aspirin played a strong inhibitory effect on AA-induced platelet aggregation [MARAA= (8.13±2.99)%]. Salvianolic acid A (10 mg·kg-1) significantly improved the neurological function, cerebral infarction volume [(10.77±7.80)%] and brain edema [(79.72±0.83)%] compared with the model group [(43.50±12.69)%, (82.25±0.89)%] (P<0.01), while the effect of aspirin (100 mg·kg-1) was not obvious. The above results suggest that compared with aspirin, salvianolic acid A provided a mild inhibitory effect on platelet aggregation and protected against cerebral ischemia induced by thrombus. Therefore, salvianolic acid A has a good application prospect in the prevention and treatment of thrombotic diseases.
